Question:

For the last quarter of 2017, are there any additional drugs with pass-through status?

Answer:

Effective October 1, 2017, the Centers for Medicare & Medicaid Services (CMS) granted outpatient prospective payment system  pass-through status to the four drugs below:

C9491 Injection, avelumab, 10 mg
C9492 Injection, durvalumab, 10 mg
C9493 Injection, edaravone, 1 mg
C9494 Injection, ocrelizumab, 1 mg

 

Facebook
Twitter
LinkedIn
Email
Print

CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.